Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.

by Yu Kato, Kimiyo Tabata, Takayuki Kimura, Ayako Yachie-Kinoshita, Yoichi Ozawa, Kazuhiko Yamada, Junichi Ito, Sho Tachino, Yusaku Hori, Masahiro Matsuki, Yukiko Matsuoka, Samik Ghosh, Hiroaki Kitano, Kenichi Nomoto, Junji Matsui, Yasuhiro Funahashi
Published 2019-01-01